The pharmacology of nitroxyl (HNO) and its therapeutic potential: not just the Janus face of NO.

Pharmacol Ther

Division of Cardiology, Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA.

Published: February 2007

Nitroxyl (HNO), the 1-electron reduced and protonated congener of nitric oxide (NO), has received recent attention as a potential pharmacological agent for the treatment of heart failure and as a preconditioning agent for the mitigation of ischemia-reperfusion injury. Interest in the pharmacology and biology of HNO has prompted examination, or in some instances reexamination, of many of its chemical properties. Such studies have provided insight into the chemical basis for the biological effects of HNO, although the biochemical mechanisms for many of these effects remain to be established. In this review, a brief description of the biologically relevant chemistry of HNO is given, followed by a more detailed discussion of the pharmacology and potential toxicology of HNO.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3501193PMC
http://dx.doi.org/10.1016/j.pharmthera.2006.11.002DOI Listing

Publication Analysis

Top Keywords

nitroxyl hno
8
hno
6
pharmacology nitroxyl
4
hno therapeutic
4
therapeutic potential
4
potential janus
4
janus face
4
face nitroxyl
4
hno 1-electron
4
1-electron reduced
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!